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Original Article
Patient Satisfaction in Postmenopausal Women
Treated with a Weekly Bisphosphonate Transitioned
to Once-Monthly Ibandronate
Sydney Lou Bonnick, M.D.,1 Stuart Silverman, M.D.,2 S. Bobo Tanner, M.D.,3 Mark Martens, M.D.,4
Gloria Bachmann, M.D.,5 Joseph D. Kohles, Ph.D.,6 and Roberto Civitelli, M.D.7
Abstract
Objective: CURRENT, a large, open-label, 6-month, multicenter study, was designed to assess patient satis-
faction levels and patient treatment preference after switching from weekly oral bisphosphonates to monthly
oral ibandronate for a period of 6 months.
Methods: This study enrolled postmenopausal women who had taken a weekly oral bisphosphonate for at least
3 months for prevention or treatment of osteoporosis or osteopenia at the time of screening. Enrolled patients
were switched to 150 mg monthly ibandronate. At baseline and 6 months, patients completed the Osteoporosis
Patient Satisfaction Questionnaire (OPSAT-Q), consisting of four domains. Scores were converted to composite
satisfaction scores (scale of 0–100). At 6 months, patients completed the Preference Questionnaire. Adverse
events were monitored throughout.
Results: The intent-to-treat population comprised 1678 patients. OPSAT-Q composite satisfaction scores im-
proved by 9 points by month 6 despite the high mean baseline summary scores (80.1 points). Convenience,
overall satisfaction, and quality of life domain scores improved by 15.6, 12, and 9.2 points, respectively. In-
creased satisfaction was reported by the majority of patients at month 6 (70.4%). Patients who reported stomach
upset or suboptimal compliance with prestudy weekly bisphosphonate treatment were more likely to report
improved satisfaction (odds ratio [OR] for stomach upset 2.98, 95% CI 1.52, 6.50, p¼ 0.0026; suboptimal com-
pliance 1.82, 95% CI 1.13–3.04, p¼ 0.017). After 6 months, 73.6% of patients preferred monthly ibandronate to
weekly bisphosphonates. The most frequently occurring adverse events were upper respiratory tract infection
(3.2% of patients), dyspepsia (2.5%), fracture (2.4%), arthralgia (2.3%), and gastroesophageal reflux disease,
diarrhea, and nausea (2.2% each).
Conclusions: Patients previously using weekly bisphosphonates reported improved satisfaction with monthly
ibandronate dosing.
Introduction
Bisphosphonates are the preferred medication treat-ment option for the management of postmenopausal os-
teoporosis.1 Although the efficacy of bisphosphonates in
increasing bone mineral density and reducing the risk of
fractures in patients with osteoporosis has been demonstrated
in clinical trials, their effectiveness in real-life clinical settings
is often compromised by poor compliance and persistence.2–4
The reasons for poor compliance and persistence with oral
bisphosphonates reflect a number of issues, including the lack
of symptoms of osteoporosis (until a fracture occurs), the
lengthy time taken before the benefits of treatment are seen,
the stringent dose administration requirements specified, and
1Clinical Research Center of North Texas, Denton, Texas.
2Cedars-Sinai Medical Center=University of California, Los Angeles, California.
3Vanderbilt University, Nashville, Tennessee.
4Planned Parenthood of Arkansas and Eastern Oklahoma Inc., Tulsa, Oklahoma.
5University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, New Jersey.
6Roche, Nutley, New Jersey.
7Washington University, St. Louis, Missouri.
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patients’ concern over possible side effects. Patients’ desire to
continue therapy has been shown to be related to satisfaction
with treatment for diseases other than osteoporosis.5,6 Evi-
dence suggests that compliance with treatment is linked to
fracture risk in postmenopausal women with osteoporosis.2,7
Thus, better compliance might be expected to improve clinical
outcomes. One approach to improving compliance with oral
bisphosphonates has been lengthening the dosing intervals
from daily to weekly and, most recently, to monthly. Quar-
terly and yearly intravenous dosing regimens have also been
developed.
The objective of the CURRENT study was to identify the
level of patient satisfaction with monthly bisphosphonate
therapy in patients previously treated with weekly bispho-
sphonates, using the Osteoporosis Patient Satisfaction Ques-
tionnaire (OPSAT-Q). An additional objective of the study
was to assess patients’ treatment preferences after 6 months of
treatment with monthly oral ibandronate.
Patients and Methods
Study design
CURRENT was a large, prospective, open-label, multicen-
ter, 6-month study. The protocol, any modifications, and ap-
propriate consent procedures were reviewed and approved
by each study site’s institutional review board. Written in-
formed consent was obtained from each patient prior to par-
ticipation in the study.
Patients
Inclusion criteria. Ambulatory postmenopausal women
were eligible for inclusion in the study if they had been re-
ceiving weekly alendronate or risedronate for the prevention
or treatment of osteoporosis or osteopenia for a minimum of
3 months, were able to understand the questionnaires, were
willing to comply with the protocol, were able to understand
and sign the written informed consent, and completed the
screening questionnaire. The screening questionnaire con-
sisted of three questions to which a Yes response indicated (1)
a preference for monthly dosing over weekly, (2) experience of
stomach upset within 48 hours of taking previous osteopo-
rosis medication more than once a month, and (3) missing
three or more doses of previous weekly osteoporosis medi-
cation in the last 3 months, respectively.
Exclusion criteria. Patients were excluded from the study
if they had a hypersensitivity to bisphosphonates, had con-
traindications to calcium or vitamin D therapy, had received
any investigational drug within 30 days, were unable to
stand=sit in an upright position for at least 60 minutes, or were
unable to swallow a tablet whole. A history of malignant
disease within the previous 10 years (except resected basal cell
cancer) or a history of liver disease, renal disease, or hyper-
calcemia was exclusionary. In addition, patients were ex-
cluded if they had a major upper gastrointestinal disease, such
as significant upper gastrointestinal bleeding, within the last
year requiring hospitalization or transfusion, recurrent peptic
ulcer disease documented by radiographic or endoscopic
means, ongoing dyspepsia or gastroesophageal reflux un-
controlled by medication, ongoing esophageal abnormalities
that delay esophageal emptying (e.g., stricture, achalasia, or
dysmotility), or active gastric=duodenal ulcers.
Patients were also excluded if the results of specified lab-
oratory tests were abnormal: alanine aminotransferase (ALT)
levels greater than twice the upper limit of the normal range,
calcium >10.5 mg=dL or <8.0 mg=dL (>2.6 or <2.0 mmol=L),
white blood cell count<2500=mL, serum albumin<3.0 g=L, or
serum creatinine >2.4 mg=dL (>210mmol=L).
Study drug administration
Participants discontinued their current bisphosphonate
treatment for a minimum of 1 week before starting 150 mg
monthly oral ibandronate. Patients took one 150 mg tablet of
ibandronate monthly for a period of 6 months for a total of six
planned doses. Patients were instructed to fast overnight for
at least 6 hours and to swallow their tablet whole with a full
glass of plain water while sitting or standing in an upright
position. They were to remain upright for 1 hour after dosing
and to wait at least 1 hour before consuming any food or
beverage other than water. Patients were instructed not to
take supplemental calcium or vitamin D or any other drug
during the postdose fasting period. Patients could elect to
receive a monthly reminder to take their medication. Com-
pliance was assessed by recording drug dispensed and re-
turned. Patients were also instructed to take supplemental
calcium and vitamin D for the full duration of the study,
which was taken in divided daily doses with meals.
Treatment satisfaction and preference assessments
The OPSAT-Q was completed at baseline and at the end of
the study. The OPSAT-Q (Table 1) is a validated questionnaire
designed to capture satisfaction with bisphosphonate treat-
ment. It comprises four domains: convenience (questions 1–6),
quality of life (questions 7 and 8), overall satisfaction (ques-
tions 9 and 10), and side effects (questions 11–16).8 All items
were scored such that higher scores represented greater sat-
isfaction or less bother=frequency of side effects. Treatment
satisfaction was measured with the OPSAT-Q composite
satisfaction score (OPSAT-Q CSS), which was the average of
the scores from the four domains of the OPSAT-Q converted
to a 0–100-point scale. In a psychometric evaluation, the in-
dividual items of the OPSAT-Q were found to be significantly
correlated with the domain scores and CSS, and the domain
scores and OPSAT-Q CSS were found to be internally con-
sistent (Cronbach’s alpha for domains ranged from 0.72 to
0.89 and was 0.87 for the CSS).8 Significant correlations were
identified between OPSAT-Q scores and global demographic
measures and quality of life scales, supporting the construct
validity of the OPSAT-Q.8
Patients also completed the Preference Questionnaire
(Pref-Q) (Table 2) at study end or on withdrawal. The Pref-Q
was adapted from a questionnaire used in an earlier study of
daily and weekly formulations of another bisphosphonate
and validated by the MEDTAP Institute Inc. (Bethesda, MD).9
Safety assessments
Patients attended monthly clinic visits during the study.
Adverse events (AEs) were monitored and recorded at visits
and through phone calls from patients throughout the study.
Patients were followed for 15 days after completion of treat-
ment to record any AEs. The results of laboratory tests at
screening and final visit were reviewed by the investigator for
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any abnormal findings. Laboratory abnormalities were not
reported as AEs unless they caused a clinically relevant con-
dition (i.e., were clinically meaningful).
Statistical analyses
All statistical analyses were predetermined and specified in
the study protocol. The populations used to analyze the study
end points were as follows: (1) the intent-to-treat (ITT) pop-
ulation, comprising all participants who received at least one
dose of study medication, (2) the safety analysis population,
comprising all patients who received at least one dose of
study medication and had at least one postbaseline safety
measurement that gave evidence of contact with a study in-
vestigator (such as any AE report, laboratory measurement,
physical examination, vital sign measurement, or other data);
and (3) the per-protocol population, comprising ITT partici-
pants without significant protocol violations. Patients with
missing responses to questions on the OPSAT-Q were ex-
cluded from the analysis for that domain of the OPSAT-Q.
Table 1. Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q)
This questionnaire asks about how satisfied or dissatisfied you are with the medication you have been taking for osteoporosis or
osteopenia. Please answer each question by marking an X in the box that most closely represents the way you feel. There are no right
or wrong answers.











1. How well the medication fits
into your overall medication schedule
& & & & & & &
2. How often you have to take the
medication
& & & & & & &
3. The convenience of taking the medication & & & & & & &
4. How easy it is to take the medication & & & & & & &
5. How easy it is to remember to take
the medication
& & & & & & &
6. The amount of time required to take the
medication, including staying upright
& & & & & & &
7. How well the medication gives you
confidence to participate in your daily
home and=or work activities
& & & & & & &
8. How well the medication gives you
confidence to be as physically active
as you’d like to be
& & & & & & &
9. Overall, how satisfied are you with
your medication?
& & & & & & &
10. How satisfied would you be to
continue taking the medication?
& & & & & & &
How bothered are you by the following side effects that you may or may not experience after taking your osteoporosis=











11. Heartburn or acid reflux & & & & &
12. Stomach upset other than heartburn or
acid reflux (such as diarrhea, nausea, vomiting,
or stomach pain)
& & & & &
13. Any other side effects you think are related
to your osteoporosis medication
& & & & &
During the past 4 weeks, on approximately how many days did you experience the following side effects associated with your
osteoporosis=osteopenia medication?
0 Days 1 Day 2 Days 3 Days More than 3 days
14. Heartburn or acid reflux & & & & &
15. Stomach upset other than heartburn or acid reflux
(such as diarrhea, nausea, vomiting, or stomach pain)
& & & & &
16. Any other side effects you think are related to
your osteoporosis medication
& & & & &
Thank you for completing this questionnaire!
ª Roche Laboratories, Inc. All rights reserved. Used with permission.
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The significance of the absolute change in scores from
baseline to month 6 for both the OPSAT-Q CSS and the in-
dividual domain scores was calculated using a t test or non-
parametric test, as appropriate. Satisfaction rates were
examined using a range of definitions for satisfaction re-
sponders: patients with OPSAT-Q CSS increases of 5% or
more, 10% or more, 5 points or more, or 10 points or more
from baseline to month 6, and the number of patients with an
OPSAT-Q CSS of >80 points at 6 months. Demographic
characteristics and responses on the screening questionnaire
were correlated with increase in the CSS using a logistic re-
gression model.
Patient preference is presented as the percentage of patients
who expressed a preference for monthly treatment, weekly
treatment, or neither. The number and proportion of patients
who had 80% compliance with 6 monthly doses of iban-
Table 2. Preference Questionnaire
INSTRUCTIONS: You have taken osteoporosis medication once a month and once a week. This questionnaire asks about what you think
of these two treatment schedules. Please answer the questions by checking the appropriate boxes.
1. Which dosing schedule do you prefer? (check one box only)
& I prefer the once-monthly dosing schedule. Go to Question 2.
& I prefer the once-weekly dosing schedule. Go to Question 3.
& I do not prefer one dosing schedule over the other dosing schedule. Go to Question 4.
2. If you prefer the once-monthly dosing schedule, please check all the statements you agree with. (check all that apply)
& The once-monthly dosing schedule causes less stomach discomfort.
& It is easier to tolerate side effects overall with the once-monthly dosing schedule.
& The once-monthly dosing schedule fits better into my lifestyle.
& It would be easier to follow the once-monthly dosing schedule for a long period of time.
& I do not agree with any of the above. Go to Question 4.
3. If you prefer the once-weekly dosing schedule, please check all the statements you agree with. (check all that apply)
& The once-weekly dosing schedule causes less stomach discomfort.
& It is easier to tolerate side effects overall with the once-weekly dosing schedule.
& The once-weekly dosing schedule fits better into my lifestyle.
& It would be easier to follow the once-weekly dosing schedule for a long period of time.
& I do not agree with any of the above. Go to Question 4.
4. Which dosing schedule is more convenient? (check one box only)
& The once-monthly dosing schedule is more convenient.
& The once-weekly dosing schedule is more convenient.
& The once-monthly dosing schedule and the once-weekly dosing schedule are equally convenient.
Thank you for completing this questionnaire!
FIG. 1. Study design and patient disposition.
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dronate and patients who requested a monthly reminder were
summarized using descriptive statistics.
Results
Study population
One hundred forty-four clinical sites in the United States
participated in this study. The disposition of patients in the
study is summarized in Figure 1. Of the 1813 patients who
entered the treatment phase, 1572, or 86.7%, completed treat-
ment. The ITT population included 1678 patients who re-
ceived at least one dose of study medication. The safety
population included the 1669 ITT patients who had at least
one safety measurement after their first dose of ibandronate.
The per-protocol population consisted of 1319 patients after
exclusion of 359 ITT patients (191 took excluded concomitant
medications, 101 did not take at least five doses of study
medication, 43 had no baseline or final OPSAT-Q CSS, 51 had
not received at least 3 months of weekly alendronate or rise-
dronate before entering the study, and 24 did not meet other
study entry criteria; some patients were excluded for multiple
reasons). The baseline demographic and clinical characteris-
tics of the 1678 patients in the ITT population are presented in
Table 3.
During the study, 6.7% of patients withdrew after taking
one or more doses of study medication. The most common
reasons for withdrawal were AEs=intercurrent illness (3.5%,
discussed in the Safety section) and consent withdrawn (1.3%).
Changes in satisfaction
Although mean OPSAT-Q CSS and OPSAT-Q domain
scores were high at baseline for weekly bisphosphonate use,
statistically significant improvement was observed in mean
OPSAT-Q CSS and in the convenience, quality of life, and
overall satisfaction OPSAT-Q domain scores after 6 months of
monthly ibandronate treatment (Table 4). The side effects
OPSAT-Q domain score remained at approximately baseline
levels. The proportion of patients who showed improvement
in satisfaction compared with baseline after 6 months was
70.4% (1087 of 1543). The proportions of patients classified
as satisfaction responders according to the prespecified defi-
nitions are summarized in Figure 2. The results for the
per-protocol population were similar to the results in the ITT
population (data not shown).
The proportions of patients with higher OPSAT-Q CSSs
compared with baseline after 6 months’ treatment with
monthly ibandronate, stratified by demographic and baseline
characteristics, are shown in Figure 3.
Using a logistic regression model, age, stomach upset
within 48 hours of taking their previous weekly bispho-
sphonate more than once a month, and missing three or more
doses of their previous weekly bisphosphonate in the past
3 months were significantly correlated with increase in
OPSAT-Q CSS at month 6 compared with baseline. Patients
<65 years of age were 1.7 times more likely to have an increase
in OPSAT-Q CSS than patients aged 65 years (estimated
odds ratio [OR] 1.70, 95% CI 1.35–2.13, p< 0.0001). Patients
who reported stomach upset within 48 hours of taking their
previous weekly bisphosphonate more than once a month at
study entry were three times more likely to be more satis-
fied at the end of the study than patients who did not (87.3%
vs. 69.5%; estimated OR, 2.98, 95% CI 1.52–6.50, p¼ 0.0026).
Table 3. Demographic and Disease Characteristics
in Intent-to-Treat Populationa






Mean SD 65.9 9.67
Range 38–95
Body mass index, kg=m2 (n¼ 1673)
Mean SD 25.8 4.98
Range 13.6–50.4
Highest level of education
Elementary school 22 (1)
Some high school 68 (4)
High school graduate=GEDb 472 (28)
Some college 553 (33)
College graduate 375 (22)
Postgraduate degree 188 (11)
Current occupation
Not working 1021 (61)
Working 656 (39)
Living environment, activity level
Home, independent 1658 (99)
Home, with assistance 13 (<1)
Assisted living facility 6 (<1)
Nursing home 1 (<1)
Major risk factors for fracturec
History of fractures as an adult 474 (28.2)
Low body weight (<58 kg) 474 (28.2)
History of fragility fracture in
first-degree relative
335 (20.0)
Current smoker 151 (9.0)
Use of oral corticosteroid
therapy for >3 months
83 (4.9)
None indicated 593 (35.3)





Osteoporosis (n¼ 1079) 58.8 51.7






medication, mean SD (n¼ 1648)
2.8 2.3
Responses to screening questionnaire
Preference for monthly dosing Yes: 1347 (80.3)
No: 329 (19.6)
Missing: 2 (0.1)
Stomach upset within 48h of dose
with weekly bisphosphonate




Missed three or more doses in





aData are presented as number (%) of patients unless otherwise
indicated. n, number of patients contributing to summary statistics.
Percentages are based on n in the column header.
bGED, general educational development (high school equivalency
certificate).
cA patient could have 1 risk factor.
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Patients who reported missing three or more doses of their
previous weekly bisphosphonate in the past 3 months at
study entry were two times more likely to be more satisfied
than patients who did not (81.9% vs. 69.4%; estimated OR
1.82, 95% CI 1.13–3.04, p¼ 0.0170).
Preference
Of 1678 patients in the ITT population, after 6 months of
treatment with monthly oral ibandronate, 87.0% (1460) com-
pleted the Pref-Q. Of the patients who completed the Pref-Q,
84.6% (1235) of patients preferred monthly treatment, 9.3%
(136) preferred weekly treatment, and 6.1% (89) did not have a
preference. Of patients who answered No to all three
screening questionnaire questions, 68.1% (224 of 329 patients)
indicated a preference for monthly ibandronate after 6 months
of treatment.
The most common reasons cited for preferring either regi-
men were that it fits the patient’s lifestyle better (patients
who preferred monthly ibandronate 69.8%, weekly bispho-
sphonates 64.7%) and is easier to follow for a long period of
time (monthly ibandronate 73.5%, weekly bisphosphonates
63.2%). Most patients thought that their preferred regimen
was more convenient than the other regimen (monthly iban-
dronate 95.3%, weekly bisphosphonates 78.7%).
Compliance
Mean treatment compliance was high, with 96.0% 15.66%
(mean SD) of planned doses taken by patients who com-
pleted the study. Overall, 94.0% (n¼ 1577) of patients in the
ITT population took at least five of the six planned doses.
Monthly reminder
Nearly half (44.8%) of the ITT population requested a
monthly reminder to take their medication. Compliance was
similar in the group of patients who requested a reminder and
the group of patients who did not request a reminder (95.1%
and 93.1% of patients, respectively, took at least five of the six
planned doses of ibandronate).
Table 4. OPSAT-Q Scores at Baseline and after 6 Months of Monthly Oral Ibandronate
Treatment in Intent-to-Treat Populationa
OPSAT-Qb domain scores
OPSAT-Q composite
satisfaction score Convenience Quality of life Overall satisfaction Side effects
Baseline (scale 0–100) 80.1 15.53 72.7 22.18 78.5 20.30 75.7 21.82 93.3 12.71
Month 6 (scale 0–100) 89.1 15.15 88.3 18.31 87.8 20.17 87.8 21.91 92.4 14.24
Change from baseline 9.0 20.80* 15.6 27.73* 9.2 26.69* 12.0 31.03* 0.9 15.67**
Percent change from baseline 17.8 44.54 41.3 125.62 19.4 58.82 30.5 91.58 1.6 30.88
aMean SD.
bOPSAT-Q, Osteoporosis Patient Satisfaction Questionnaire.
*p< 0.0001; **p¼ 0.02.
FIG. 2. Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) satisfaction responder rates using various definitions of
satisfaction response.
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Safety
In the safety population (n¼ 1669), the proportion of pa-
tients who reported at least one AE was 41.3% (n¼ 689) during
the treatment phase. Forty patients (2.4%) had a fracture-
related AE. Other AEs occurring with an incidence of 2%
were upper respiratory tract infection (3.2%, n¼ 54), dyspep-
sia (2.5%, n¼ 42), arthralgia (2.3%, n¼ 39), gastroesophageal
reflux disease (2.2%, n¼ 37), diarrhea (2.2%, n¼ 36), and nau-
sea (2.2%, n¼ 36). Most AEs were judged by the investigators
to be mild to moderate in intensity. The proportion of patients
who experienced AEs that were of severe intensity was 8%
(n¼ 133). The most common severe intensity AEs were diar-
rhea (7 patients), upper abdominal pain (6 patients), and back
pain, chest pain, and shoulder pain (5 patients each).
The proportion of patients with AEs assessed by the in-
vestigator as possibly or probably drug related was 11.3%
(n¼ 188). The most common investigator-perceived drug-
related AEs were dyspepsia (1.9%, n¼ 32), gastroesophageal
reflux disease (1.5%, n¼ 25), nausea (1.3%, n¼ 21), arthralgia
(1.0%, n¼ 17), and diarrhea (0.8%, n¼ 13).
The overall incidence of serious AEs was 3.2% (n¼ 54). The
most common serious AEs were chest pain (4 patients), atrial
fibrillation (3 patients), breast cancer (3 patients), and syncope
(3 patients). All serious AEs were judged by the investigators
to be either unrelated or remotely related to ibandronate
treatment.
Discussion
Ibandronate is approved for the prevention and treatment
of postmenopausal osteoporosis10 and is the first bispho-
sphonate available for use in a monthly dosing regimen. The
objective of CURRENT was to assess patient satisfaction with
monthly ibandronate in a population of former weekly bis-
phosphonate users.
FIG. 3. Proportion of patients with improvement in Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) composite
satisfaction score at 6 months compared with baseline, by demographic and clinical characteristics.
*Odds ratio¼ 1.7 (95% confidence interval 1.35–2.13); p< 0.0001. BMD, bone mineral density; PMO, postmenopausal oste-
oporosis.
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The mean level of satisfaction after treatment with monthly
ibandronate was greater than at baseline (OPSAT-Q mean
CSS 89.1 at month 6 vs. 80.1 at baseline). A total of 70.4% of
patients had improved satisfaction scores following 6 months
of monthly ibandronate treatment, despite relatively high
baseline satisfaction scores. Patients <65 years were more
likely to be satisfied than patients 65 years. Patients who
reported previous gastrointestinal intolerance or noncompli-
ance were more likely to be satisfied after 6 months of
monthly ibandronate treatment than those who did not.
Monthly ibandronate was generally well tolerated, and all
serious AEs reported were considered by the investigators to
be unrelated or remotely related to ibandronate treatment.
Preference for monthly oral ibandronate vs. a weekly bi-
sphosphonate was also documented in two independently
conducted multicenter clinical trials, Boniva Alendronate
Trial in Osteoporosis (BALTO) I and II, in which patients were
randomized to receive monthly ibandronate or weekly alen-
dronate for 3 months or 12 weeks, respectively, using a cross-
over design.11,12 In these two studies, the Pref-Q was
completed at the conclusion of the two crossover periods. The
majority of patients preferred the monthly dosing schedule
(71.4% of patients expressed a preference in BALTO I and
70.6% in BALTO II) and found it more convenient (74.6% of
patients who expressed a preference in BALTO I and 76.6% in
BALTO II).11,12 The most common reasons given for patient
preference in both studies were ease of following the treat-
ment for a long time and the ability of the regimen to fit better
into the patient’s lifestyle, as was seen in the CURRENT study.
Potential limitations of the present study include its open-
label design and the possible effect of study participation itself
on satisfaction. The open-label study design was necessary
given the objectives of the study; however, it is possible that
patients more likely to prefer monthly dosing were also more
likely to enter the study, consistent with the high proportion
of patients expressing a preference for monthly dosing on the
screening questionnaire. However, prior use of a weekly bi-
sphosphonate before beginning a monthly bisphosphonate is
likely to be representative of the experience of many patients
in a clinical setting.
Compliance with monthly ibandronate in this study was
high. This may have been influenced by such factors as se-
lection bias toward patients more likely to take osteoporosis
medication, as indicated by the high baseline level of com-
pliance with weekly bisphosphonates, and the effect of trial
participation on patients’ inclination to continue taking the
drug. Compliance was assessed by recording drug dispensed
and returned, although this does not necessarily indicate that
the medication was taken as prescribed and may overestimate
actual compliance with treatment. As noted previously, there
was a high level of baseline satisfaction and compliance in this
study. Therefore, these results may not be applicable to a
population of women in whom baseline satisfaction and
compliance are low. Nevertheless, in spite of apparently good
compliance and a low rate of gastrointestinal side effects with
weekly dosing based on screening questionnaire responses
and satisfaction with weekly bisphosphonate treatment based
on the baseline OPSAT-Q CSS, satisfaction scores significantly
improved after 6 months of monthly ibandronate treatment.
Thus, this study may provide useful information on how
patients receiving a weekly bisphosphonate might perceive
monthly ibandronate treatment after switching. The duration
of this study was relatively short at 6 months. The high level of
satisfaction, compliance, and preference for monthly iban-
dronate observed over 6 months may not correspond to a high
level of satisfaction, compliance, or preference in patients
treated for longer periods.
Finally, the study population was 95% Caucasian, and 94%
had at least a high school diploma or its equivalent. The re-
sults of this study may not be applicable to women of other
races or ethnicity or of different educational backgrounds.
A patient’s preference for one treatment over another ad-
dresses his or her reaction to the treatment.6 Preference may
impact patient satisfaction13 and, ultimately, compliance with
treatment. Compliance with treatment has been shown to be
associated with reduced fracture risk in osteoporosis7,14,15 and
is, therefore, an important treatment goal for osteoporosis.
The results of this study suggest that monthly ibandronate is
associated with a high level of patient satisfaction with oral
bisphosphonate treatment in general and specifically in pa-
tients who were previously gastrointestinal intolerant or
missed doses of their previous weekly bisphosphonate ther-
apy. This may prove helpful in encouraging patients to con-
tinue bisphosphonate treatment and, thus, realize its benefits
in reducing fracture risk associated with osteoporosis.
Results from this trial add to our understanding of patient
satisfaction with bisphosphonate treatment. They suggest
that patients who switch from a weekly regimen of alen-
dronate or risedronate to a monthly regimen of ibandronate
may experience increased satisfaction with their bispho-
sphonate treatment based on data from a validated self-
reported satisfaction questionnaire.
Conclusions
Data from this large multicenter trial of postmenopausal
women, previously receiving a weekly bisphosphonate,
showed that the majority of patients reported improved sat-
isfaction when switched to monthly ibandronate even though
baseline satisfaction was high. A greater proportion of pa-
tients preferred monthly oral ibandronate to their prior
weekly bisphosphonate treatment after 6 months of therapy.
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